David Avigan, MD, Harvard Medical School, Boston, MA, comments on the challenge of finding a target for CAR-T therapy in acute myeloid leukemia (AML), highlighting the potential role of vaccines in this disease. Dr Avigan explains that it appears that vaccines may have a role in preventing relapse rather than attempting to bring patients into remission. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.